{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:09:59Z","timestamp":1791896999146,"version":"4.3.4"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Shionogi B.V."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carbapenem-resistant Acinetobacter baumannii infections are difficult to treat and are a significant public health threat due to intrinsic\/acquired resistance and limited treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, observational cohort study in patients receiving cefiderocol via Shionogi's early access program for Acinetobacter spp infections (1 April 2020\u201330 April 2021; 27 sites; Italy, Spain, Germany, France). Primary outcome was clinical success, defined as clinical resolution of infection at day 14 or day 28 survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 147 patients were included. Primary infection sites were respiratory (65.3%) and bloodstream (unknown source [15.6%]; catheter-related [10.9%]); 24.5% of patients had polymicrobial infection. Of 136 patients in intensive care (92.5%), 85.3% (116\/136) received mechanical ventilation. Septic shock (55.6% [70\/126]) and coronavirus disease 2019 (COVID-19) (81.6%) were prevalent. Prior to cefiderocol, 85.0% of patients received gram-negative treatment, 61.2% received \u22652 antimicrobials, and most received colistin (58.5%; median duration, 11.5 days). Cefiderocol monotherapy was used in 30.6% of patients. Clinical success rate was 53.1% and was higher in patients without septic shock (62.5%), without COVID-19 (77.8%), and with lower Sequential Organ Failure Assessment (SOFA) scores (quartile 1 [median, 3; range, 0\u20135]: 82.9%). Day 28 survival was 44.9% and was higher in patients without septic shock (60.7%), without COVID-19 (59.3%), with lower SOFA score (quartile 1: 82.9%), and receiving first-line cefiderocol (68.2% [15\/22]). Resolution of infection at day 14 occurred in 39.5% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite use in complex patients with limited treatment options and high septic shock\/COVID-19 rates, cefiderocol treatment was associated with an overall clinical success rate of 53%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofad329","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T09:29:15Z","timestamp":1688376555000},"source":"Crossref","is-referenced-by-count":30,"title":["Carbapenem-Resistant\n                    <i>Acinetobacter<\/i>\n                    spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8273-7601","authenticated-orcid":false,"given":"Maddalena","family":"Giannella","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Istituto di Ricovero e Cura a Carattere Scientifico - Policlinico di Sant'Orsola , Bologna , Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna , Bologna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Verardi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Shionogi B.V. , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Karas","sequence":"additional","affiliation":[{"name":"Medical Affairs, Shionogi B.V. , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasania","family":"Abdel Hadi","sequence":"additional","affiliation":[{"name":"Unidad de Cuidados Intensivos, Hospital General Universitario , Ciudad Real , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dupont","sequence":"additional","affiliation":[{"name":"Anesthesiology and Critical Care Medicine, Centre Hospitalier Universitaire d\u2019Amiens Picardie , Amiens , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Santerre Henriksen","sequence":"additional","affiliation":[{"name":"Medical Affairs, Shionogi B.V. , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cooper","sequence":"additional","affiliation":[{"name":"Global Epidemiology and Real-World Evidence, Shionogi B.V. , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-8796","authenticated-orcid":false,"given":"Marco","family":"Falcone","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Pisa , Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ARES Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toussaint","family":"Muheberimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Fiore","family":"Bavaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Dalfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barchiesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylenia","family":"Farinaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Temperoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Parruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Coladonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Rapacchiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurenzia","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Torti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele Durante","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Iossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arta","family":"Karruli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Carannante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pallotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Maria","family":"Seminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Sottotetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Casolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Vanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cristini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Raumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"di Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Cubattoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta Di","family":"Lauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Cultrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasania Abdel","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Hidalgo","family":"Tenorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P\u00e9rez","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Canas-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis L\u00f3pez-Urrutia","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Balandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Lepeule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Jarczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"2023072516445801000_ofad329-B1","article-title":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis","author":"World Health Organization","year":"2017"},{"key":"2023072516445801000_ofad329-B2","article-title":"Rapid risk assessment: carbapenem-resistant Acinetobacter baumannii in healthcare settings","author":"European Centre for Disease Prevention and Control","year":"2016"},{"key":"2023072516445801000_ofad329-B3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1017\/ice.2021.144","article-title":"Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: a multicenter before-and-after cross-sectional study","volume":"43","author":"Pascale","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023072516445801000_ofad329-B4","doi-asserted-by":"crossref","first-page":"10103","DOI":"10.1038\/s41598-021-89516-6","article-title":"The lower respiratory tract microbiome of critically ill patients with COVID-19","volume":"11","author":"Gaibani","year":"2021","journal-title":"Sci Rep"},{"key":"2023072516445801000_ofad329-B5","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.cmi.2021.06.001","article-title":"The interface between COVID-19 and bacterial healthcare-associated infections","volume":"27","author":"O\u2019Toole","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2023072516445801000_ofad329-B6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1186\/s12879-021-06496-8","article-title":"Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study","volume":"21","author":"Pascale","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2023072516445801000_ofad329-B7","article-title":"2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline","author":"World Health Organization","year":"2019"},{"key":"2023072516445801000_ofad329-B8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","article-title":"All-cause mortality rates in adults with carbapenem-resistant gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies","volume":"20","author":"Lodise","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023072516445801000_ofad329-B9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhin.2021.04.001","article-title":"Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients","volume":"113","author":"Silva","year":"2021","journal-title":"J Hosp Infect"},{"key":"2023072516445801000_ofad329-B10","doi-asserted-by":"crossref","first-page":"e02562-17","DOI":"10.1128\/AAC.02562-17","article-title":"Comparison of septic shock due to multidrug-resistant Acinetobacter baumannii or Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit patients","volume":"62","author":"Russo","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023072516445801000_ofad329-B11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023072516445801000_ofad329-B12","article-title":"Fetcroja (cefiderocol) summary of product characteristics","author":"Shionogi B.V","year":"2023"},{"key":"2023072516445801000_ofad329-B13","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023072516445801000_ofad329-B14","article-title":"Colistin breakpoints guidance document 2022","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2022"},{"key":"2023072516445801000_ofad329-B15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023072516445801000_ofad329-B16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023072516445801000_ofad329-B17","first-page":"651","article-title":"Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023072516445801000_ofad329-B18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2020.09.019","article-title":"Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii","volume":"23","author":"Oliva","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2023072516445801000_ofad329-B19","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023072516445801000_ofad329-B20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/phar.2660","article-title":"Successful prolonged treatment of a carbapenem-resistant Acinetobacter baumannii hip infection with cefiderocol: a case report","volume":"42","author":"Rose","year":"2022","journal-title":"Pharmacotherapy"},{"key":"2023072516445801000_ofad329-B21","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1093\/jacamr\/dlab055","article-title":"Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection","volume":"3","author":"Mabayoje","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023072516445801000_ofad329-B22","doi-asserted-by":"crossref","first-page":"ofaa150","DOI":"10.1093\/ofid\/ofaa150","article-title":"Case report: successful rescue therapy of extensively drug-resistant Acinetobacter baumannii osteomyelitis with cefiderocol","volume":"7","author":"Dagher","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023072516445801000_ofad329-B23","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1093\/jac\/dkz318","article-title":"Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report","volume":"74","author":"Trecarichi","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023072516445801000_ofad329-B24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2021.06.035","article-title":"Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: recto: cefiderocol causing acute interstitial nephritis","volume":"109","author":"Cipko","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2023072516445801000_ofad329-B25","doi-asserted-by":"crossref","first-page":"ofaa185","DOI":"10.1093\/ofid\/ofaa185","article-title":"Cefiderocol for extensively drug-resistant gram-negative bacterial infections: real-world experience from a case series and review of the literature","volume":"7","author":"Zingg","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023072516445801000_ofad329-B26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antibiotics11010003","article-title":"Cefiderocol for severe carbapenem-resistant Acinetobacter baumannii pneumonia: towards the comprehension of its place in therapy","volume":"11","author":"Rando","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023072516445801000_ofad329-B27","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023072516445801000_ofad329-B28","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023072516445801000_ofad329-B29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2023072516445801000_ofad329-B30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13054-019-2663-7","article-title":"The SOFA score\u2014development, utility and challenges of accurate assessment in clinical trials","volume":"23","author":"Lambden","year":"2019","journal-title":"Crit Care"},{"key":"2023072516445801000_ofad329-B31","doi-asserted-by":"crossref","first-page":"e0079522","DOI":"10.1128\/aac.00795-22","article-title":"Reply to Epling and Powers, \u201cCefiderocol and the need for higher-quality evidence: methods matter for patients.\u201d","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023072516445801000_ofad329-B32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1086\/657243","article-title":"How soon is now? The urgent need for randomized, controlled trials evaluating treatment of multidrug-resistant bacterial infection","volume":"51","author":"Paterson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023072516445801000_ofad329-B33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40560-015-0077-4","article-title":"Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"3","author":"Inchai","year":"2015","journal-title":"J Intensive Care"},{"key":"2023072516445801000_ofad329-B34","doi-asserted-by":"crossref","first-page":"e1225-8","DOI":"10.1016\/j.ijid.2013.07.014","article-title":"Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors","volume":"17","author":"Chaari","year":"2013","journal-title":"Int J Infect Dis"},{"key":"2023072516445801000_ofad329-B35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jhin.2006.06.025","article-title":"The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes","volume":"64","author":"Robenshtok","year":"2006","journal-title":"J Hosp Infect"},{"key":"2023072516445801000_ofad329-B36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/anae.15425","article-title":"Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies","volume":"76","author":"Armstrong","year":"2021","journal-title":"Anaesthesia"},{"key":"2023072516445801000_ofad329-B37","article-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 12.0","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2022"},{"key":"2023072516445801000_ofad329-B38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s15010-021-01643-4","article-title":"Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit","volume":"50","author":"Russo","year":"2022","journal-title":"Infection"},{"key":"2023072516445801000_ofad329-B39","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)","volume":"46","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med"},{"key":"2023072516445801000_ofad329-B40","doi-asserted-by":"crossref","first-page":"n579","DOI":"10.1136\/bmj.n579","article-title":"Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012\/1: matched cohort study","volume":"372","author":"Challen","year":"2021","journal-title":"BMJ"},{"key":"2023072516445801000_ofad329-B41","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023072516445801000_ofad329-B42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023072516445801000_ofad329-B43","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40121-022-00598-9","article-title":"Outcomes with cefiderocol treatment in patients with bacteraemia enrolled into prospective phase 2 and phase 3 randomised clinical studies","volume":"11","author":"Paterson","year":"2022","journal-title":"Infect Dis Ther"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad329\/50800581\/ofad329.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/7\/ofad329\/50958975\/ofad329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/7\/ofad329\/50958975\/ofad329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T12:46:45Z","timestamp":1690289205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad329\/7219203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad329","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,7,1]]},"article-number":"ofad329"}}